Biogen Clinical Trials

Clinical trials sponsored by Biogen — phases, conditions and reported results. Data from ClinicalTrials.gov.

• Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Scler
  Phase 3 · Relapsing-Remitting Multiple Sclerosis · Completed · May 19, 2026
• Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid
  Phase 1/2 · Ocular Cicatricial Pemphigoid · Completed · Apr 21, 2011
• Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephr
  Phase 2 · Immunoglobulin A Nephropathy · Completed · Apr 28, 2026
• A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease
  Phase 2 · Alzheimer's Disease · Completed · Mar 4, 2026
• A Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in People Aged 16 to 40 With Friedrei
  Phase 2 · Friedreich Ataxia · Completed · Nov 29, 2022
• A Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropathic Pain
  Phase 2 · Diabetic Peripheral Neuropathic Pain · Terminated · Dec 15, 2025
• A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab
  Phase 3 · Multiple Sclerosis, Relapsing-Remitting · Terminated · Nov 25, 2025
• A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of
  Phase 3 · Relapsing Forms of Multiple Sclerosis · Completed · Oct 24, 2025
• A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Pres
  Phase 2 · Spinal Muscular Atrophy · Completed · Oct 20, 2025
• A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With
  Phase 1/2 · Amyotrophic Lateral Sclerosis · Terminated · Oct 9, 2025
• A Study to Evaluate the Pharmacokinetics, Safety and Immunogenicity of BIIB800 Subcutaneously (SC) Compared to
  Phase 1 · Healthy Volunteer · Completed · Oct 6, 2025
• Long-Term Evaluation of BIIB067 (Tofersen)
  Phase 3 · ALS Caused by Superoxide Dismutase 1 Mutation · Completed · Aug 29, 2025
• A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL
  Phase 2/3 · Alport Syndrome · Completed · Oct 11, 2023
• Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertensi
  Phase 3 · Pulmonary Hypertension · Terminated · Oct 12, 2023
• Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT
  Phase 2 · Pulmonary Arterial Hypertension · Completed · Jul 23, 2021

Trials by company

PfizerMerck (MSD)RocheNovartisAstraZenecaJohnson & Johnson (Janssen)Bristol Myers SquibbSanofiGSKEli LillyAbbVieAmgenBayerBoehringer IngelheimNovo NordiskTakedaGilead SciencesModernaBioNTechRegeneronVertexBiogenDaiichi SankyoAstellas PharmaEisaiOtsukaServierIncyteCelltrionSamsung BioepisHanmi PharmaceuticalYuhan

All trials